Who is sponsoring NCT03043742?

NCT03043742 is sponsored by Michael Sekela.

What drugs are being tested in NCT03043742?

Interventions in NCT03043742: Bone Marrow Derived Autologous CD133+ Selected Cell Product.

What condition does NCT03043742 study?

NCT03043742 studies Chronic Ischemic Heart Disease.

Is NCT03043742 still recruiting?

NCT03043742 is currently completed. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT03043742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease

Completed Phase 1 Last updated 11 December 2020

What this trial tests

Phase 1 trial testing Bone Marrow Derived Autologous CD133+ Selected Cell Product in Chronic Ischemic Heart Disease in 8 participants. Completed in 12 November 2020.

Timeline

12 July 2016

Primary endpoint
12 November 2020

12 November 2020

Quick facts

Lead sponsor	Michael Sekela
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	12 July 2016
Primary completion	12 November 2020
Estimated completion	12 November 2020
Sites	1 location across United States

Drugs / interventions tested

Bone Marrow Derived Autologous CD133+ Selected Cell Product — full drug profile →

Conditions studied

Chronic Ischemic Heart Disease — all drugs for Chronic Ischemic Heart Disease →

Sponsor

Michael Sekela — full company profile →

Who can join

18 and older, any sex, with Chronic Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assess the safety and effectiveness of stem cell application with regard to improvement in regional myocardial function in patients receiving Trans-Myocardial Laser Revascularization (TMR) and stem cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Locoregional delivery of stem cell-based therapies.
Ng NN, Thakor AS. · · 2020 · cited 24× · PMID 32522806 · DOI 10.1126/scitranslmed.aba4564

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03043742 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Sekela
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03043742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing